SCHEMBL4469410

SCHEMBL4469410

CC#CCn1c(Br)nc2c1c(=O)n(Cc1ccc(C#N)cc1)c(=O)n2C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 8/20 0.55
RAB9A P51151 1/20 0.50
FAP Q12884 1/20 0.50
TSHR P16473 4/20 0.48
POLB P06746 1/20 0.48
LMNA P02545 5/20 0.48
NPSR1 Q6W5P4 2/20 0.48
ALDH1A1 P00352 4/20 0.47
HIF1A Q16665 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CHRM1 P11229 1/20 0.47
KDM4E B2RXH2 1/20 0.46
HPGD P15428 2/20 0.46
MAPK1 P28482 2/20 0.46
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
PKM P14618 1/20 0.44
STAT6 P42226 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482398 0.88 DPP4 (0.71) DPP4RAB9AFAPTSHRLMNA
SCHEMBL4487837 0.82 KMT2A (0.60) DPP4RAB9ATSHRLMNAALDH1A1
SCHEMBL3918926 0.81 DPP4 (0.55) DPP4RAB9AFAPTSHRPOLB
SCHEMBL3975290 0.81 DPP4 (0.50) DPP4RAB9AFAPTSHRPOLB
SCHEMBL20041950 0.80 DPP4 (0.63) DPP4RAB9AFAPTSHRLMNA
SCHEMBL4464028 0.80 DPP4 (0.48) DPP4FAPPOLBCHRM1MEN1
SCHEMBL497449 0.79 DPP4 (0.50) DPP4RAB9ATSHRLMNANPSR1
SCHEMBL20041938 0.79 DPP4 (0.65) DPP4TSHRPOLBLMNANPSR1
SCHEMBL20041912 0.78 DPP4 (0.65) DPP4TSHRLMNASMN1; SMN2HPGD
SCHEMBL3930764 0.78 DPP4 (0.47) DPP4RAB9AFAPTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495002-B2 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-24 US disclosed
US-20060079541-A1 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079541-A1 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions DPP4, DPP7, DPP3 DPP4 1/4885RAB9A 4077/4885FAP 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.